T he U.S. Food and Drug Administration (FDA) banned the use of Red Dye No.3 in foods and has given drug manufacturers until Jan. 18, 2028, and food manufacturers until Jan. 15, 20

The Food and Drug Administration announced last week that it will revoke authorization for FD&C Red No. 3 in food and ingested drugs under the Delaney Clause of the Federal Food, Drug, and Cosmetic Act. Red No. 3, a synthetic food dye, gives products like candies, frosting and frozen desserts their bright, cherry-red color.

The FDA just announced changes to help make berries sold in the U.S. safer to eat, lowering the odds you’ll get norovirus or hepatitis A.

The Food and Drug Administration announced it was overhauling its berry safety strategy. Here's what to know, plus which are most likely to be contaminated.

Experts say it's common to wait until new teams are in place but is a concern if it means "going back to a prior approach of silencing the agencies". View on euronews

The Food and Drug Administration released on Tuesday its long-awaited proposal to require food manufacturers to put some nutrition facts on the front of packages, in a bid to nudge Americans and ...

The new Trump administration could put a stop to pending litigation on the abortion pill mifepristone and other federal abortion policies through changes at the Department of Health and Human Services, according to a top anti-abortion lawyer involved in several pending cases.

Dr. Dorothy Fink, the acting secretary for the Department of Health and Human Services under President Donald Trump, has instructed the heads of every federal health agency to stop public communication.

After the Red No. 3 ban, there are now eight color additives approved by the FDA. They are FD&C Blue No. 1, FD&C Blue No. 2, FD&C Green No. 3, Orange B, Citrus Red No. 2, FD&C Red No. 40, FD&C Yellow No. 5 and FD&C Yellow No. 6.

Drug firm Lupin on Friday said it has received approval from the US health regulator to market a generic HIV medication in the US market.

Generally, you can count on drugmakers for a steady revenue performance -- since patients need their medicines, revenue holds up well at these companies regardless of general economic conditions. But certain pharmaceutical and biotech stocks stand out from time to time,